- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00727779
Mechanisms by Which Strength Training Ameliorates the Metabolic Syndrome
February 13, 2015 updated by: Charles A. Stuart, East Tennessee State University
Prevention and treatment strategies for diabetes use exercise as the cornerstone.
Even though endurance training and strength training both improve insulin resistance, strength training may be better suited for persons at risk for type 2 diabetes.
We will expand our pilot studies of muscle adaptation induced by resistance exercise training to determine the biochemical mechanisms that will cause people with the Metabolic Syndrome to secure major benefit from intense strength training.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Life style alterations can be powerful deterrents to developing type 2 diabetes and are cornerstones of the treatment of this condition.
Both aerobic and resistance exercise improve diabetes blood glucose control and insulin resistance.
These two types of exercise appear to exert their effects on different muscle fiber types - red for endurance and white for strength.
Similar to the effects of endurance exercise training, strength training increases muscle glucose transporter isoform 4 (GLUT4), but in contrast, mitochondria numbers do not increase.
We hypothesize (1) that strength training in persons with pre-diabetes may be effective in reversing insulin resistance by novel mechanisms that are distinct from the endurance training-induced mitochondrial biogenesis.
We further hypothesize (2) that resistance exercise training enhances whole body insulin action primarily by increasing the white fiber size via the protein kinase mammalian target of rapamycin (mTOR) and improves insulin-stimulated glucose uptake by increased GLUT4 expression primarily in white fibers of the trained muscles.
In this proposal, we will perform eight weeks of progressive strength training on ten subjects with the Metabolic Syndrome who are at high risk for developing type 2 diabetes and on ten sedentary control subjects.
This project builds on our experience with a study of focused resistance training whose results are presented in this application.
In this pilot study, subjects exercised on stationary bicycles for six weeks causing muscle GLUT4 and phopho-mTOR to increase substantially, but maximal oxygen uptake (VO2max), phospho-AMP-activated protein kinase (AMPK), peroxisome proliferator-activated receptor-γ co-activator (PGC-1α), and mitochondrial markers did not change.
Our hypotheses will be tested by two Specific Aims.
(1) Subjects at high risk for diabetes will undergo progressively increasing intensity resistance exercise training and increased strength and improved insulin responsiveness will both be quantified to demonstrate significant benefit, and (2) quantify the effect of resistance exercise training on anatomic and functional adaptation in muscle.
We will characterize fiber type, fiber size, fiber-specific changes in mitochondrial DNA and enzymes, fiber-specific changes in the principle glucose transporters in muscle (GLUT4, GLUT5, and GLUT12), and evaluate changes in two distinct intramuscular pathways (AMPK, mTOR) and regulatory factors (PGC-1α, PPARγ, PPARδ) using immunoblots of muscle subcellular fractions and immunohistochemical techniques.
These evaluations of molecular mechanisms will also include assessing changes in full human Affymetrix gene array data that may move us to new potential resistance training-regulated gene targets.
It is the long-term goal of this team of investigators to understand the interplay between life style changes and pharmacological agents in the prevention and treatment of diabetes.
Our results will facilitate the development of more effective clinical options to turn back the epidemic of obesity and diabetes in the United States.
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Tennessee
-
Johnson City, Tennessee, United States, 37614
- East Tennessee State Univ
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
obese family history of diabetes
Exclusion Criteria:
non-obese diabetes
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: metabolic syndrome
intervention is to undergo eight weeks of progressive strength training; metabolic syndrome subjects will have baseline and post-intervention assessments including muscle biopsies and insulin clamps
|
eight weeks of progressively increasing resistance training will be done in both groups side-by-side
|
Active Comparator: control subjects
intervention is to undergo eight weeks of progressive strength training; non-obese sedentary subjects will have the same assessments as the metabolic syndrome subjects and exercise training simultaneously.
|
eight weeks of progressively increasing resistance training will be done in both groups side-by-side
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
euglycemic clamp steady state glucose infusion rate (clamp GIR)
Time Frame: pre- post- intervention
|
pre- post- intervention
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
GLUT4 content of muscle
Time Frame: pre- post- intervention
|
pre- post- intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Charles A Stuart, MD, East Tennessee State University, Johnson City, TN
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Stuart CA, Yin D, Howell ME, Dykes RJ, Laffan JJ, Ferrando AA. Hexose transporter mRNAs for GLUT4, GLUT5, and GLUT12 predominate in human muscle. Am J Physiol Endocrinol Metab. 2006 Nov;291(5):E1067-73. doi: 10.1152/ajpendo.00250.2006. Epub 2006 Jun 27.
- Reeds DN, Stuart CA, Perez O, Klein S. Adipose tissue, hepatic, and skeletal muscle insulin sensitivity in extremely obese subjects with acanthosis nigricans. Metabolism. 2006 Dec;55(12):1658-63. doi: 10.1016/j.metabol.2006.08.006.
- Stuart CA, Howell ME, Yin D. Overexpression of GLUT5 in diabetic muscle is reversed by pioglitazone. Diabetes Care. 2007 Apr;30(4):925-31. doi: 10.2337/dc06-1788. Epub 2007 Jan 24.
- Moorman J, Zhang Y, Liu B, LeSage G, Chen Y, Stuart C, Prayther D, Yin D. HIV-1 gp120 primes lymphocytes for opioid-induced, beta-arrestin 2-dependent apoptosis. Biochim Biophys Acta. 2009 Aug;1793(8):1366-71. doi: 10.1016/j.bbamcr.2009.05.007. Epub 2009 May 27.
- Copland JA, Pardini AW, Wood TG, Yin D, Green A, Bodenburg YH, Urban RJ, Stuart CA. IGF-1 controls GLUT3 expression in muscle via the transcriptional factor Sp1. Biochim Biophys Acta. 2007 Nov-Dec;1769(11-12):631-40. doi: 10.1016/j.bbaexp.2007.08.002. Epub 2007 Sep 4.
- Layne AS, Nasrallah S, South MA, Howell ME, McCurry MP, Ramsey MW, Stone MH, Stuart CA. Impaired muscle AMPK activation in the metabolic syndrome may attenuate improved insulin action after exercise training. J Clin Endocrinol Metab. 2011 Jun;96(6):1815-26. doi: 10.1210/jc.2010-2532. Epub 2011 Apr 20.
- Stuart CA, Ross IR, Howell ME, McCurry MP, Wood TG, Ceci JD, Kennel SJ, Wall J. Brain glucose transporter (Glut3) haploinsufficiency does not impair mouse brain glucose uptake. Brain Res. 2011 Apr 12;1384:15-22. doi: 10.1016/j.brainres.2011.02.014.
- Stuart CA, Howell ME, Cartwright BM, McCurry MP, Lee ML, Ramsey MW, Stone MH. Insulin resistance and muscle insulin receptor substrate-1 serine hyperphosphorylation. Physiol Rep. 2014 Dec 3;2(12):e12236. doi: 10.14814/phy2.12236. Print 2014 Dec 1.
- Stuart CA, South MA, Lee ML, McCurry MP, Howell ME, Ramsey MW, Stone MH. Insulin responsiveness in metabolic syndrome after eight weeks of cycle training. Med Sci Sports Exerc. 2013 Nov;45(11):2021-9. doi: 10.1249/MSS.0b013e31829a6ce8.
- Stuart CA, McCurry MP, Marino A, South MA, Howell ME, Layne AS, Ramsey MW, Stone MH. Slow-twitch fiber proportion in skeletal muscle correlates with insulin responsiveness. J Clin Endocrinol Metab. 2013 May;98(5):2027-36. doi: 10.1210/jc.2012-3876. Epub 2013 Mar 20.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2008
Primary Completion (Actual)
June 1, 2013
Study Completion (Actual)
June 1, 2013
Study Registration Dates
First Submitted
July 31, 2008
First Submitted That Met QC Criteria
July 31, 2008
First Posted (Estimate)
August 4, 2008
Study Record Updates
Last Update Posted (Estimate)
February 16, 2015
Last Update Submitted That Met QC Criteria
February 13, 2015
Last Verified
February 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R15DK080488 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Syndrome
-
Universidad de los Andes, ChileCompleted
-
Taipei Medical University WanFang HospitalUnknownMetabolic Cardiovascular SyndromeTaiwan
-
SanofiBristol-Myers SquibbCompletedMetabolic Syndrome xUnited States
-
Mayo ClinicCompleted
-
University of HohenheimGerman Federal Ministry of Education and ResearchCompleted
-
The Catholic University of KoreaCompletedMetabolic Syndrome X | Metabolic Cardiovascular Syndrome | Insulin Resistance Syndrome X | Dysmetabolic Syndrome XKorea, Republic of
-
Charite University, Berlin, GermanyRecruitingMetabolic Syndrome, Protection AgainstGermany
-
Wageningen University and ResearchPhilips Healthcare; TNO; Friesland Campina; Albert Heijn; Menzis; Smart with food; Vi... and other collaboratorsCompletedMetabolic Syndrome, Protection AgainstNetherlands
-
Cairo UniversityCompletedMetabolic Syndrome in WomenEgypt
-
Andalas UniversityHasanuddin University; Universitas Sumatera UtaraCompletedMetabolic Syndrome, Protection AgainstIndonesia
Clinical Trials on strength training
-
University of AarhusUnknownOsteoarthritis, KneeDenmark
-
University of FloridaCompleted
-
Universidad Autónoma de Manizales, ColombiaCompletedFemale | Volleyball | PlayerColombia
-
Norwegian University of Science and TechnologyCompleted
-
Christian DallCompletedHeart Failure | Ischemic Heart Disease | Heart Transplant RecipientsDenmark
-
Lislei Jorge PatrizziCompleted
-
Eunice Kennedy Shriver National Institute of Child...Shriners Hospitals for Children; University of DelawareUnknownSpastic Diplegic Cerebral PalsyUnited States
-
Isra UniversityCompleted
-
Vrije Universiteit BrusselRecruitingHealthy Aged VolunteersBelgium
-
University of GiessenHannover Medical SchoolUnknownType 2 DiabetesGermany